CN105687358A - Medicine for treating vitiligo - Google Patents
Medicine for treating vitiligo Download PDFInfo
- Publication number
- CN105687358A CN105687358A CN201610191681.3A CN201610191681A CN105687358A CN 105687358 A CN105687358 A CN 105687358A CN 201610191681 A CN201610191681 A CN 201610191681A CN 105687358 A CN105687358 A CN 105687358A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- relieving
- decoct
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/238—Saposhnikovia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/19—Acanthaceae (Acanthus family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a medicine for treating vitiligo. The medicine is prepared from the following raw medicinal materials in parts by weight: 7 parts of radix saposhnikoviae, 22 parts of trollius chinensis, 7 parts of diverse wormwood herb, 7 parts of aesculus chinensis bge, 6 parts of radix ligustici sinensis, 12 parts of fiveleaf akebia fruit and 6 parts of kadsura japonica. In the invention, the radix saposhnikoviae is used for dispelling wind and releasing exterior, eliminating dampness and relieving pain and relieving convulsion and stopping itching; the trollius chinensis is used for clearing heat and removing toxin and cooling blood and stopping bleeding; the diverse wormwood herb is used for breaking blood stasis and dredging channels, stopping bleeding and diminishing swelling and promoting digestion and resolving accumulation; the aesculus chinensis bge is used for soothing liver and regulating qi and smoothing middle and relieving pain; the radix ligustici sinensis is used for dispelling wind and eliminating dampness and dissipating cold and relieving pain; the fiveleaf akebia fruit is used for soothing liver and harmonizing stomach, activating blood and relieving pain, softening hardness and dissipating mass and promoting urination; and the kadsura japonica is used for dispelling wind and resolving phlegm, dredging collaterals and relieving spasm and removing dampness and toxin. The medicines are combined to realize the functions of relieving stuffy orifices and activating blood, tonifying and replenishing heart and spleen, dredging meridians/channels and removing dampness and stopping itching. Clinical experiments prove that the medicine can be used for safely and effectively treating vitiligo.
Description
Technical field
The present invention relates to a kind of Chinese medicine, be specifically related to a kind of for treating leukodermic medicine。
Background technology
Vitiligo be the abnormal posteriority limitation of a kind of common metabolism of pigment or general property skin pigment depigmentation sick。Cause owing to the melanocyte function of skin disappears, but mechanism is not clear。The each position of whole body can occur, and is common in the finger back of the body, wrist, forearm, face, neck and surrounding genital etc.。Female genitalia also can occur, and young women is in the majority。Without obvious inducement, doctor trained in Western medicine think be likely to relevant with factors such as heredity, autoimmune, endocrine and spirit。Due to etiology unknown, treatment is also without desirable way。
Chinese medicine to the understanding of primary disease very early, the record of existing treatment " in vain place " in " 52 Bingfang ", and have second prescription。" General Treatise on the Cause and Symptoms of Diseases " in Tang of Sui epoch, Prescriptions Worth Thousand Gold for Emergencies begin to claim " leucoderma ", " vitiligo " or " white lump ", and point out that its pathogenesis is for " ailment said due to cold or exposure is won in skin, and vim and vigour are got along well "。
The cause of disease
Primary disease pathogenic factor is unclear。Recent study thinks relevant with following factor:
1. theory of heredity
Vitiligo can occur in twins and family, illustrates that heredity plays an important role in vitiligo is fallen ill。Research thinks that vitiligo has incomplete penetrance, and gene has multiple pathogenic sites。
2. theory of autoimmunity
Vitiligo can merge autoimmune disease, such as thyroid disease, diabetes, chronic adrenal hypofunction, pernicious anemia, rheumatic arthritis, malignant melanoma etc.。Serum can also detect the specific antibody of multiple organ, such as anti-thyroid antibody, anti-gastric parietal cell antibody, antiadrenal antibody, anti-parathyroid gland antibody, smooth muscle antibody, anti-melanocyte antibody etc.。
3. spirit and neuro chemistry theory
Nervous and Mental Factors and leukodermic morbidity are closely related, and most patient is in onset or skin lesion developmental stage spiritedness wound, hypertonicity, depressed or dejected。White macula place teleneuron has degeneration, also supports neuro chemistry theory。
4. melanocyte autoclasia theory
Antibody and T lymphocyte can be produced in patients with vitiligo body, illustrate that immunoreation may result in melanocyte and is destroyed。And cell itself synthesis toxicity melanocyte precursor and some cause that melanocyte is likely to selectively destruction by the chemical substance of skin depigmentation。
5. trace element deficiency theory
In patients with vitiligo blood and skin, copper or ceruloplasmin concentrations reduce, and cause that tyrosinase activity reduces, thus affect the metabolism of melanocyte。
6. other factors
Wound, solar exposure and some photosensitive medicines also can bring out vitiligo。
Clinical manifestation
Sex no significant difference, each age group all can be fallen ill, but sends out well with teenager。Skin lesion is depigmentation speckle, is often milky, it is possible to for lightpink, smooth surface is without erythra。White macula boundary is clear, and edge pigment compared with normal skin increases, and in white macula, hair normally or bleaches。Pathological changes is apt to occur in is irradiated and damage by friction position by sunlight, and how symmetrical disease damage is。White macula is also often pressed nerve segment distribution and is zonation。Except skin lesion, inside lip, labia, glans penis and foreskin, mucosa is also often got involved。
The many no conscious symptons of primary disease, small number of patients is at premorbid or has local, affected part scratchiness simultaneously。Vitiligo often accompanies other autoimmune diseasees, such as diabetes, thyroid disease, adrenal insufficiency, scleroderma, atoipc dermatitis, alopecia areata etc.。Concrete typing is as follows:
1. topical type
Focal type a: place or many places white macula are confined to a region, but are not distributed in sections;
Unilateral type (segmental pattern) a: place or many places white macula are sections distribution, suddenly disappear in midline;
Mucosa type: only involve mucosa。
2. type it is dispersed in
Homeliness type: extensively and be dispersed in the white macula of distribution;
Face acra type: be distributed in face and extremity;
Mixed type: segmental pattern, face acra type and/or homeliness type mixed distribution。
3. general hair style
Depigmentation all or almost all。
The vitiligo of more than 90% is to be dispersed in type, and in remaining vitiligo, topical type is more more than general hair style。
This disease can be divided into again perfect form and forme fruste two kinds according to disease damage place depigmentation situation。The former is to dihydroxyphenyl alanine (DOPA) reaction negative, and melanocyte disappears, and therapeutic response is poor。The latter is to DOPA reacting positive, and melanocyte does not disappear and is only decreased number, cures probability big。
Drug therapy
1. psoralen and derivant thereof: irradiation ultraviolet radiation after as oral in methoxsalen。
2. megavitamin: such as vitamin B complex, vitamin C, Citrin long-term taking。
3. the treatment such as the medicine of useful cupric: as 0.5% copper-bath is administered orally。
4. immunomodulator: levamisole is administered orally, lyophilized bacillus calmette-guerin vaccine (BCG) intramuscular injection, oral Bovine Placenta etc.。
5. skin irritant local is embrocated: making skin be inflamed reaction, promote pigment hypertrophy, dust head has 30% psoralea tincture, chlormethine ethanol, phenol (pure carbolic acid), 25%~50% trichloroacetic acid, Mylabris tincture etc.。This method is only applicable to small pieces skin lesion, and after painting, skin lesion place may occur in which bulla。
6. corticosteroid hormone: package treatment such as local such as various corticosteroid hormones such as propanoic acid beclometasone ointment, halometasone cream, omcilon carbamide ointment etc.。
7. treatment by Chinese herbs: start with marrow, whole body therapeutic, make disease start to take a turn for the better, human body recovers normal physiological function。
Medical material involved in the present invention is all recorded in " China's book on Chinese herbal medicine " as seen。
Summary of the invention
It is desirable to provide one is used for treating leukodermic medicine, by selecting suitable medical material and proportioning thereof, reach safely and effectively to cure leukodermic purpose。
In order to achieve the above object, the present invention is by the following technical solutions:
One is used for treating leukodermic medicine, it is characterised in that it is to be prepared from by the raw medicinal material of following weight proportion: go back to 7 parts of cloud, Flos Trollii 22 parts, crow rattan dish 7 parts, Semen Aesculi 7 parts, Rhizoma Ligustici 6 parts, Fructus Akebiae 12 parts, fragrant Soviet Union 6 parts。
Illustrate the method have the benefit that below in conjunction with theories of Chinese materia medica
It has been recognised by the inventors that vitiligo is caused by the not flourish skin of blood, but the cause of disease of the not flourish skin of blood and evolution then each family thereof how is caused to have again different views。End is got up, and mainly has following two。Qi depression to blood stasis: internal injury caused by excess of seven emotions, mechanism of qi loses smooth, hyperamization network stasis blocking;Or by the scorching inclined victory of natural endowment, feel ailment said due to cold or exposure again, stop up stagnant flesh table;Or controlled for a long time by pathogenic factor, cloudy blood in-fighting, nutrient QI and blood being insufficient, and QI and blood is difficult to walk, the not flourish skin of blood forms primary disease。Deficiency of the liver and kindey: deficiency of kidney-YIN, essence does not change blood, liver lose moisten foster, deficiency of liver-blood, not flourish skin and hair and bleach;Or deficiency of the liver and kindey, multiple wind-engaging invades blood stasis, it is possible to cause that primary disease occurs。Many scholars think, qi depression to blood stasis and deficiency of the liver and kindey are the keys of primary disease, on this basis, all can being invaded by exogenous pathogen (such as wind, rheumatism, damp and hot etc.), three influences each other sometimes and has an effect, and simply lays particular stress on different。Therefore blood circulation promoting and blood stasis dispelling, dredging collateral honor skin, adjusting and reinforcing liver and kidney, nourishing blood to expel wind are then taked in treatment。
The present invention uses: returning cloud expelling pathogenic wind from the body surface, removing dampness to relieve pain, spasmolytic is antipruritic;Flos Trollii heat-clearing and toxic substances removing, cooling blood for hemostasis;Crow rattan dish removing blood stasis with potent drugs stimulates the menstrual flow, hemostasia and detumescence, promoting digestion and removing stagnation;Semen Aesculi depressed liver-energy dispersing and QI regulating, alleviating distention in middle-JIAO pain relieving;Rhizoma Ligustici expelling wind and dampness, dispersing cold for relieving pain;Fructus Akebiae dispersing the stagnated liver-QI for regulating the stomach, promoting blood circulation and stopping pain, hard masses softening and resolving, diuresis;Fragrant Soviet Union dispelling pathogenic wind and eliminating phlegm, dredging collateral relieving convulsion, removing dampness and detoxicating。All medicines share, and reach sensible to invigorate blood circulation, effect of invigorating the heart and spleen, dredging the meridian, removing dampness to relieve itching。
Below in conjunction with clinical laboratory data, beneficial effects of the present invention is described:
1, physical data
Inventor collects 74 example patients with vitiligo between in April ,-2015 in October, 2012 altogether。It is randomly divided into: treatment group 41 example, matched group 33 example。Male 24 examples of wherein treatment group, female 17 example, 26~58 years old age, the course of disease 3 months~11 years;Matched group man 18 examples, female 15 example, between 27~57 years old age, the course of disease 2 months~10 years。The data such as two groups of sexes, age, courses of disease there was no significant difference, and has comparability。
Diagnostic criteria
1. the morbidity day after tomorrow, agnogenic depigmentation speckle。White macula is often creamy white, and size, form differ, and on it, hair can normally or bleach。
2. the feature according to erythra distribution is divided into homeliness type (topical type, general hair style, distribute type, acra type) and segmental pattern。Homeliness type skin lesion is generally symmetrical distribution, can be confined to some position or distribute, general whole body。Segmental pattern is generally one side, and white macula is distributed along a certain tegumentary nerve joint domination district。According to whether state of an illness activity was divided into for two phases: progressive stage and stable phase。Progressive stage is that former white macula is still expanding, obscurity boundary, and can have a new skin lesion, can have isomorphic response;Stable phase is that former white macula stops development, and sends out skin lesion without new, without isomorphic response。
3. the course of disease is slow, without obvious subjective symptoms。
4. hypopigmentation that other reason causes or the white macula that depigmentation causes can be got rid of。
1. inclusive criteria meets diagnostic criteria;2. age 18~70 years old;3. compliance is good;4. Informed Consent Form is signed voluntarily。
Exclusion standard 1. gestation, women breast-feeding their children;2. suffer from severe cardiac, lung, liver, renal disease patient;3. spiritedness systemic disease, it is impossible to partner treatment person;4. through the patient of other drug treatment after morbidity。
2, Therapeutic Method
The capsule that the oral present invention specific embodiment 3 for the treatment of group prepares, every day 3 times。Treat 2 months。
Matched group is administered orally 8-MOP sheet, each 10mg, every day 3 times。Treat 2 months。
3, criterion of therapeutical effect and therapeutic outcome
3.1 criterions of therapeutical effect
1. recovery from illness: white macula recovers normal color of the leather person completely;
2. effective: part white macula disappears or reduces recovery normal skin tone, has a large amount of pigmentation in white macula, grow pigment island or rubescent dimmed person;
3. invalid: vitiliginous skin color area is unchanged。
3.2 treatment statistical results are in Table 1。
1 liang of table group comparitive study
Visible, vitiligo can safely and effectively be treated by the medicine that the present invention prepares, and cure rate is high。
Detailed description of the invention
In order to be more fully understood that and implement the present invention, further illustrate the present invention below in conjunction with specific embodiment。
Embodiment 1
Weigh: go back to 7 grams of cloud, Flos Trollii 22 grams, crow rattan dish 7 grams, Semen Aesculi 7 grams, Rhizoma Ligustici 6 grams, Fructus Akebiae 12 grams, fragrant Soviet Union 6 grams;Add 8 times amount water, decoct 1.5 hours, filter;Filtering residue adds 6 times amount water, decocts 1 hour, filters;Merging filtrate, is concentrated into 120 grams, must meet the decoct of one day consumption of adult normal。
For treating vitiligo。Oral, daily once。
Embodiment 2
Weigh: go back to 7 grams of cloud, Flos Trollii 22 grams, crow rattan dish 7 grams, Semen Aesculi 7 grams, Rhizoma Ligustici 6 grams, Fructus Akebiae 12 grams, fragrant Soviet Union 6 grams;Add 10 times amount water, decoct 2 hours, filter;Filtering residue adds 8 times amount water, decocts 1.5 hours, filters;Merging filtrate, concentration, dry, packaging, the powder of one day consumption of adult normal must be met。
For treating vitiligo。Oral, every bu is taken for twice sooner or later。
Embodiment 3
Weigh: go back to 7 grams of cloud, Flos Trollii 22 grams, crow rattan dish 7 grams, Semen Aesculi 7 grams, Rhizoma Ligustici 6 grams, Fructus Akebiae 12 grams, fragrant Soviet Union 6 grams;Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentration, dry, load capsule shells, the capsule of one day consumption of adult normal must be met。
For treating vitiligo。Oral, every bu morning, noon and afternoon take for three times。
Claims (4)
1. one kind is used for treating leukodermic medicine, it is characterised in that it is to be prepared from by the raw medicinal material of following weight proportion: go back to 7 parts of cloud, Flos Trollii 22 parts, crow rattan dish 7 parts, Semen Aesculi 7 parts, Rhizoma Ligustici 6 parts, Fructus Akebiae 12 parts, fragrant Soviet Union 6 parts。
2. one as claimed in claim 1 is used for treating leukodermic medicine, it is characterised in that its preparation method is: weigh: go back to 7 parts of cloud, Flos Trollii 22 parts, crow rattan dish 7 parts, Semen Aesculi 7 parts, Rhizoma Ligustici 6 parts, Fructus Akebiae 12 parts, fragrant Soviet Union 6 parts;Add 8 times amount water, decoct 1.5 hours, filter;Filtering residue adds 6 times amount water, decocts 1 hour, filters;Merging filtrate, is concentrated into 120 parts, obtains decoct;Above-mentioned part each means weight portion。
3. one as claimed in claim 1 is used for treating leukodermic medicine, it is characterised in that its preparation method is: weigh: go back to 7 parts of cloud, Flos Trollii 22 parts, crow rattan dish 7 parts, Semen Aesculi 7 parts, Rhizoma Ligustici 6 parts, Fructus Akebiae 12 parts, fragrant Soviet Union 6 parts;Add 10 times amount water, decoct 2 hours, filter;Filtering residue adds 8 times amount water, decocts 1.5 hours, filters;Merging filtrate, concentration, dry, packaging, obtain powder;Above-mentioned part each means weight portion。
4. one as claimed in claim 1 is used for treating leukodermic medicine, it is characterised in that its preparation method is: weigh: go back to 7 parts of cloud, Flos Trollii 22 parts, crow rattan dish 7 parts, Semen Aesculi 7 parts, Rhizoma Ligustici 6 parts, Fructus Akebiae 12 parts, fragrant Soviet Union 6 parts;Add 6 times amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentration, dry, load capsule shells, obtain capsule;Above-mentioned part each means weight portion。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610191681.3A CN105687358A (en) | 2016-03-30 | 2016-03-30 | Medicine for treating vitiligo |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610191681.3A CN105687358A (en) | 2016-03-30 | 2016-03-30 | Medicine for treating vitiligo |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105687358A true CN105687358A (en) | 2016-06-22 |
Family
ID=56218516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610191681.3A Pending CN105687358A (en) | 2016-03-30 | 2016-03-30 | Medicine for treating vitiligo |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105687358A (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103239646A (en) * | 2013-05-26 | 2013-08-14 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating leucoderma and preparation method thereof |
CN105079233A (en) * | 2014-05-09 | 2015-11-25 | 蒋盘君 | Traditional Chinese medicine decoction for treating leucoderma |
CN105288072A (en) * | 2015-12-01 | 2016-02-03 | 陈焕斌 | Traditional Chinese medicine for treating leucoderma |
-
2016
- 2016-03-30 CN CN201610191681.3A patent/CN105687358A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103239646A (en) * | 2013-05-26 | 2013-08-14 | 广州市云桥生物科技有限公司 | Chinese medicine effective part composition for treating leucoderma and preparation method thereof |
CN105079233A (en) * | 2014-05-09 | 2015-11-25 | 蒋盘君 | Traditional Chinese medicine decoction for treating leucoderma |
CN105288072A (en) * | 2015-12-01 | 2016-02-03 | 陈焕斌 | Traditional Chinese medicine for treating leucoderma |
Non-Patent Citations (1)
Title |
---|
杨素清等: "王玉玺教授运用如意黑白散治疗白癜风的临床经验", 《中医药学报》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102091258B (en) | Chinese medicinal composition for dispelling scars and preparation method thereof | |
CN102049008B (en) | Traditional Chinese medicine composition for treating chloasma and preparation method thereof | |
CN102293874B (en) | Multifunctional medicinal pillow and preparation method thereof | |
CN103463539A (en) | Drug for treating eczema, and preparation method and use thereof | |
CN101966298B (en) | Traditional Chinese medicine for treating wind-cold numbness | |
CN101637512B (en) | Traditional Chinese medicine preparation for treating vitiligo | |
CN102302733B (en) | Oral Chinese medicinal composition for treating ovarian cyst | |
CN101057922B (en) | Traditional Chinese medicine preparation for treating vitiligo | |
CN102430097A (en) | Chinese medicine for treating vitiligo | |
CN102908582B (en) | Traditional Chinese medicine composition for treating blood stasis type abdominal mass for women and preparation method thereof | |
CN106344772A (en) | traditional Chinese medicine composition for treating rhinitis, external preparation and preparation method thereof | |
CN108403869B (en) | Traditional Chinese medicine composition for removing chloasma and preparation method thereof | |
CN101797371B (en) | Drug combination for weight-reducing massage | |
CN105687358A (en) | Medicine for treating vitiligo | |
CN112043773A (en) | Intelligent system preparation for conditioning physique and preventing and treating various psoriasis and preparation method thereof | |
CN101229221B (en) | Chinese traditional medicine for treating thromboangiitis obliterans and preparing method thereof | |
CN108815332A (en) | A kind of composition of tonifying kidney and strengthening yang and the preparation method and application thereof | |
CN105497157A (en) | Medicine used for treating alopecia cicatrisata | |
CN111643606B (en) | Gel plaster for treating insomnia and preparation method thereof | |
CN104606636A (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
CN105796658A (en) | Meidcament for treating female climacteric syndromes | |
CN106511711A (en) | Traditional Chinese medicine formula for treating breast cancer | |
Kumar et al. | CLINICAL EVALUATION OF VIDANGADI PRADEHA & ARAGVADHADI UDVARTANA IN EK-KUSHTHA (PSORIASIS) | |
CN116270809A (en) | Traditional Chinese medicine compound prescription for soothing nerves, relieving itching and strengthening spleen for treating atopic dermatitis and preparation method thereof | |
CN101653543B (en) | Medicine for curing scrofula |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160622 |